Acute Heart Failure in Elderly Patients Admitted to the Emergency Department with Acute Dyspnea: a Multimarker Approach Prognostic Study

NCT ID: NCT06692439

Last Updated: 2024-11-18

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Total Enrollment: 185 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2024-11-30
• Study Completion Date: 2025-09-30

Brief Summary

Background and Rationale:

Acute dyspnea is a frequent presenting symptom in emergency departments (ED), with acute heart failure (AHF) being the most common cause leading to hospitalization in elderly patients. AHF in this population presents unique challenges in diagnosis, management, and risk stratification. Current tools for severity assessment and risk stratification (NT-proBNP and echocardiography) have shown limited evolution over the past 20 years and remain insufficient, particularly for elderly patients who predominantly present with heart failure with preserved ejection fraction (HFpEF). Recent European Society of Cardiology (ESC) and American Heart Association (AHA) guidelines specifically call for research on biomarkers within a multi-marker strategy for AHF risk stratification.

Research Hypothesis:

The study hypothesizes that a combination of biomarkers (NT-proBNP, High-sensitivity Troponin I, ST2, Galectin-3, CD146 and suPAR) will provide prognostic value and effectively stratify risk for early outcomes (90-day mortality and hospital readmission) in patients aged ≥75 years presenting to the ED with acute dyspnea and diagnosed with AHF.

Primary Objective:

To evaluate the prognostic value of six biomarkers, both individually and in combination, for predicting 90-day all-cause mortality or ED readmission in elderly patients (≥75 years) presenting with acute dyspnea and diagnosed with AHF.

Study Design:

This is a prospective prognostic study including patients from 7 emergency departments from university and non-university hospitals in France.

Study Population:

(I) Patients aged ≥75 years presenting to the ED with acute dyspnea meeting at least two criteria:

• Respiratory rate ≥25/min
• PaO2 ≤70 mmHg
• SpO2 ≤92% on room air
• PaCO2 ≥45 mmHg and pH ≤7.35
• Oxygen requirement

(ii) Have confirmed AHF diagnosis by two expert reviewers based on clinical data, laboratory results (excluding NT-proBNP), ECG, imaging, and specialized cardiac echo

Primary Endpoint:

Composite endpoint of 90-day all-cause mortality or ED readmission, as recommended by the ESC for evaluating early outcomes in AHF patients.

Analysis plan includes:

• ROC curves for optimal biomarker thresholds
• Kaplan-Meier survival analysis with log-rank tests
• Univariate and multivariate Cox regression analyses
• Bootstrap methods for confidence intervals

Conditions

Acute Heart Failure (AHF); Dyspnoea

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

acute heart failure

The presence or absence of acute left heart failure (gold standard) was determined through diagnosis by two experts (a cardiologist and an emergency physician) based on:

1. Data collected in the ED and during hospitalization: Clinical examination and history, Current medications, Hemodynamic parameters, ECG, Chest X-ray, Emergency interventions, Clinical and paraclinical findings during hospitalization

2. Biological assays (excluding NT-proBNP)

3. Echocardiography performed by a cardiologist within 24 hours of admission, including: Left Ventricular Ejection Fraction, Segmental wall motion, Presence of valvular disease, Transmitral flow, Tissue Doppler E' velocity

anticipated, n = 185/450 (41%)

No interventions assigned to this group

no acute heart failure

The presence or absence of acute left heart failure (gold standard) was determined through diagnosis by two experts (a cardiologist and an emergency physician) based on:

1. Data collected in the ED and during hospitalization: Clinical examination and history, Current medications, Hemodynamic parameters, ECG, Chest X-ray, Emergency interventions, Clinical and paraclinical findings during hospitalization

2. Biological assays (excluding NT-proBNP)

3. Echocardiography performed by a cardiologist within 24 hours of admission, including: Left Ventricular Ejection Fraction, Segmental wall motion, Presence of valvular disease, Transmitral flow, Tissue Doppler E' velocity

anticipated, n = 265/450 (59%)

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

1. Present to the ED with acute dyspnea meeting at least two criteria:

• Respiratory rate ≥25/min
• PaO2 ≤70 mmHg
• SpO2 ≤92% on room air
• PaCO2 ≥45 mmHg and pH ≤7.35
• Oxygen requirement

2. Have confirmed AHF diagnosis by two expert reviewers based on clinical data, laboratory results (excluding NT-proBNP), ECG, imaging, and specialized cardiac echo

3. Provided written consent for data use in the READ-MA-PRONO study

Exclusion Criteria

• No written consent for data use in the READ-MA-PRONO study

• Minimum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Centre Hospitalier Universitaire de Besancon

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Frédéric MAUNY, MD, PhD

Role: STUDY_CHAIR

CHU Besançon

Marc PUYRAVEAU, MSc

Role: STUDY_CHAIR

CHU Besançon

Central Contacts

Omide TAHERI, MD, PhD

Role: CONTACT

omide.taheri@gmail.com

03.81.66.70.28

Thibaut DESMETTRE, MD, PhD

Role: CONTACT

thibaut.desmettre@hug.ch

Other Identifiers

2022/725

Identifier Type: -

Identifier Source: org_study_id